Work Here?
About Enveda Biosciences
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Late Stage VC
Total Funding
$342.2M
Headquarters
Boulder, Colorado
Founded
2019
Overview
Enveda Biosciences focuses on drug discovery by exploring the largely unknown chemical compounds found in nature. With only 5% of these compounds currently understood, Enveda aims to uncover new medicines from this vast resource. The company utilizes advanced technologies like machine learning, metabolomics, and robotics to speed up the drug discovery process. Their proprietary platform allows for high-throughput experiments, enabling them to conduct numerous tests quickly and build a comprehensive dataset of small molecules, which are essential for developing new drugs. Enveda differentiates itself from competitors by its emphasis on the untapped chemical space of the natural world and its ability to rapidly identify potential drug leads. The goal of Enveda is to expand the knowledge of natural compounds and provide new treatment options for various diseases through partnerships with healthcare and pharmaceutical companies.
Simplify's Take
What believers are saying
- Enveda secured $130 million in funding, boosting its drug discovery efforts.
- Collaborations with Microsoft enhance Enveda's AI-driven drug discovery capabilities.
- Growing demand for novel small molecules benefits Enveda's natural chemical exploration.
What critics are saying
- Competition from AI-driven drug discovery companies like Insilico Medicine is increasing.
- Regulatory challenges exist as frameworks for AI-based drug discovery are still developing.
- Rapid technological advancements may render current AI tools obsolete, requiring R&D investment.
What makes Enveda Biosciences unique
- Enveda uses AI to explore uncharted chemical space for drug discovery.
- Their platform enables high-throughput experiments for rapid testing and data collection.
- Enveda collaborates with tech giants like Microsoft to enhance AI capabilities.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$342.2M
Above
Industry Average
Funded Over
5 Rounds
Benefits
Traditional or Roth 401k matching of 4% (100% of your contributions up to 4% of your annual compensation)
Medical, dental and vision insurance. 100% coverage of employee premiums and 33% coverage of dependents
Unlimited paid time off
Flexible work hours and paid parental leave
Company-wide weeklong break to recharge in addition to 8 observed holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO.Model N appoints Bret Connor as Chief Executive Officer. The Board of Directors of Blue Shield of California appoints Lois Quam as chief executive officer to lead Blue Shield of California, the first woman to serve as CEO in the health plan’s 86-year history. She joined the company as president in 2024.   Yaqrit, a late-stage biotech and medtech company developing lifesaving treatments for advanced liver diseases appoints Troels Jordansen has joined Yaqrit as Chief Executive Officer.OP Solutions names Michael Kallish as Chief Executive Officer, effective immediately.Access TeleCare appoints Dr. Michael Genovese to Chief Medical Officer for Behavioral Health.Enveda appoints Jason Kim as Chief Financial Officer (CFO).Eko Health appoints of Justin Spencer as Chief Financial Officer (CFO). (Pull from site)Qure.ai appoints Jim Mercadante as its new Chief Commercial Officer. (Pull from site)Symplr, appoints Dr
Enveda, a biotechnology company using AI to translate life's chemistry into new medicines, today announced the appointment of Jason Kim as Chief Financial Officer (CFO).
Enveda Therapeutics Inc., a Colorado-based startup, has secured $130 million in funding, co-led by Kinnevik and FPV Ventures, with participation from Baillie Gifford, Lux Capital, and others. This follows a $55 million raise in June and $51 million last year. The company is using AI to identify drug candidates and has begun a Phase I trial for an eczema treatment. Enveda's valuation has increased, and it plans a trial for an inflammatory bowel disease drug in 2025.
AI has so far failed to transform health care, but investors are betting on its potential.
BOULDER - Enveda Biosciences, a biotechnology company using artificial intelligence to translate nature into new medicines, has appointed Dr. José Trevejo as chief medical officer and head of clinical pipeline strategy.
There are no jobs for Enveda Biosciences right now.
Find jobs on Simplify and start your career today
About Enveda Biosciences
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Late Stage VC
Total Funding
$342.2M
Headquarters
Boulder, Colorado
Founded
2019
There are no jobs for Enveda Biosciences right now.
Find jobs on Simplify and start your career today